Analysts Are Neutral on Top Healthcare Picks

By Jason Carr

Analysts fell to the sidelines weighing in on Lannett (NYSE: LCI) and Insys Therapeutics (NASDAQ: INSY) with neutral ratings,indicating that the experts are neither bullish nor bearish on the stocks.

Lannett (NYSE: LCI)

In a report released today, Rohit Vanjani from Oppenheimer assigned a Hold rating to Lannett (NYSE: LCI). The company’s shares opened today at $18.05, close to its 52-week low of $16.75.

According to TipRanks.com, Vanjani is a 4-star analyst with an average return of 4.7% and a 47.2% success rate. Vanjani covers the Healthcare sector, focusing on stocks such as Zynerba Pharmaceuticals, ANI Pharmaceuticals, and Endo International.

Lannett has an analyst consensus of Moderate Buy.

Insys Therapeutics (NASDAQ: INSY)

In a report released today, Marcus Y. Ho from Oppenheimer assigned a Hold rating to Insys Therapeutics (NASDAQ: INSY). The company’s shares opened today at $10.69, close to its 52-week low of $10.01.

According to TipRanks.com, Ho is a 1-star analyst with an average return of -26.4% and a 0.0% success rate. Ho covers the Healthcare sector, focusing on stocks such as Endo International, Foamix Pharma, and Opko Health.

Currently, the analyst consensus on Insys Therapeutics is Moderate Buy and the average price target is $22, representing a 105.8% upside.

In a report released today, RBC Capital also reiterated a Hold rating on the stock.